Lipid emulsion administered intravenously or orally attenuates triglyceride accumulation and expression of inflammatory markers in the liver of nonobese mice fed parenteral nutrition formula

J Nutr. 2013 Mar;143(3):253-9. doi: 10.3945/jn.112.169797. Epub 2013 Jan 16.

Abstract

The accumulation of hepatic TG and development of hepatic steatosis (HS) is a serious complication of the use of parenteral nutrition (PN) formulas containing a high percentage of dextrose. But whether fat emulsions or other nutrients can ameliorate the induction of HS by high-carbohydrate diets is still uncertain. We hypothesized that administration of a lipid emulsion (LE; Intralipid) and/or the vitamin A metabolite retinal (RAL) will reduce hepatic TG accumulation and attenuate indicators of inflammation. C57BL/6 male mice were fed PN formula as their only source of hydration and nutrition for 4-5 wk. In Expt. 1, mice were fed PN only or PN plus treatment with RAL (1 μg/g orally), LE (200 μL i.v.), or both LE and RAL. In Expt. 2, LE was orally administered at 4 and 13.5% of energy to PN-fed mice. All PN mice developed HS compared with mice fed normal chow (NC) and HS was reduced by LE. The liver TG mass was lower in the PN+LE and PN+RAL+LE groups compared with the PN and PN+RAL groups (P < 0.01) and in the 4% and 13.5% PN+LE groups compared with PN alone. Hepatic total retinol was higher in the RAL-fed mice (P < 0.0001), but RAL did not alter TG mass. mRNA transcripts for fatty acid synthase (Fasn) and sterol regulatory element-binding protein-1c (Srebpf1) were higher in the PN compared with the NC mice, but FAS protein and Srebpf1 mRNA were lower in the PN+LE groups compared with PN alone. The inflammation marker serum amyloid P component was also reduced. In summary, LE given either i.v. or orally may be sufficient to reduce the steatotic potential of orally fed high-dextrose formulas and may suppress the early development of HS during PN therapy.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Animals
  • Dietary Fats / pharmacology
  • Dietary Fats / therapeutic use
  • Fat Emulsions, Intravenous / pharmacology
  • Fat Emulsions, Intravenous / therapeutic use*
  • Fatty Acid Synthases / genetics
  • Fatty Acid Synthases / metabolism
  • Fatty Liver / etiology
  • Fatty Liver / metabolism
  • Fatty Liver / prevention & control*
  • Glucose / adverse effects
  • Inflammation / blood
  • Inflammation / etiology
  • Inflammation / prevention & control*
  • Inflammation Mediators / blood*
  • Liver / drug effects*
  • Liver / metabolism
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Parenteral Nutrition / adverse effects*
  • RNA, Messenger / metabolism
  • Retinaldehyde / pharmacology
  • Retinaldehyde / therapeutic use
  • Serum Amyloid P-Component / metabolism
  • Sterol Regulatory Element Binding Protein 1 / genetics
  • Sterol Regulatory Element Binding Protein 1 / metabolism
  • Triglycerides / metabolism*
  • Vitamin A / blood

Substances

  • Dietary Fats
  • Fat Emulsions, Intravenous
  • Inflammation Mediators
  • RNA, Messenger
  • Serum Amyloid P-Component
  • Sterol Regulatory Element Binding Protein 1
  • Triglycerides
  • Vitamin A
  • Fatty Acid Synthases
  • Glucose
  • Retinaldehyde